Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nuvion SMART Anti-CD3 antibody: Phase I

In a 15-patient Phase I study, PDLI said that Nuvion gave no toxicities or allergic or inflammatory

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE